{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T15:37:54Z","timestamp":1782747474832,"version":"3.54.5"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,3,2]],"date-time":"2025-03-02T00:00:00Z","timestamp":1740873600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,3,2]],"date-time":"2025-03-02T00:00:00Z","timestamp":1740873600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004324","name":"Astellas Pharma US","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004324","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Universit\u00e4tsklinikum Schleswig-Holstein - Campus L\u00fcbeck"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1007\/s12325-025-03132-8","type":"journal-article","created":{"date-parts":[[2025,3,2]],"date-time":"2025-03-02T18:35:46Z","timestamp":1740940546000},"page":"1919-1934","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Cardiovascular Risks and Survival with Abiraterone vs Enzalutamide in Chemotherapy-Na\u00efve Metastatic Castration-Resistant Prostate Cancer in Germany: AVENGER Study"],"prefix":"10.1007","volume":"42","author":[{"given":"Axel S.","family":"Merseburger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugen","family":"Dornstauder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carsten-Henning","family":"Ohlmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Armen","family":"Aprikian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophia","family":"Junker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp","family":"Hahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Chilelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Stoelzel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexis","family":"Serikoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan G.","family":"Spitzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,2]]},"reference":[{"key":"3132_CR1","unstructured":"Robert Koch Institute, Association of Population-Based Cancer Registries in Germany. Cancer in Germany 2017\/2018. 13th ed. Robert Koch Institute, Berlin; 2022."},{"key":"3132_CR2","volume-title":"Global cancer burden growing, amidst mounting need for services","author":"World Health Organization","year":"2024","unstructured":"World Health Organization. Global cancer burden growing, amidst mounting need for services. Geneva: WHO; 2024."},{"key":"3132_CR3","unstructured":"Deutsche Gesellschaft f\u00fcr Urologie e.V. S3-Leitlinie Prostatakarzinom. Version 6.2. 2021. https:\/\/www.leitlinienprogramm-onkologie.de\/fileadmin\/user_upload\/Downloads\/Leitlinien\/Prostatatkarzinom\/Version_6\/LL_Prostatakarzinom_Langversion_6.2.pdf. Accessed 13 Aug 2024."},{"key":"3132_CR4","doi-asserted-by":"publisher","first-page":"e333","DOI":"10.1093\/ehjci\/jeac106","volume":"23","author":"AR Lyon","year":"2022","unstructured":"Lyon AR, L\u00f3pez-Fern\u00e1ndez T, Couch LS, et al. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). Eur Heart J Cardiovasc Imag. 2022;23:e333\u2013465. https:\/\/doi.org\/10.1093\/ehjci\/jeac106.","journal-title":"Eur Heart J Cardiovasc Imag"},{"key":"3132_CR5","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1016\/j.annonc.2020.06.011","volume":"31","author":"C Parker","year":"2020","unstructured":"Parker C, Castro E, Fizazi K, et al. Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2020;31:1119\u201334. https:\/\/doi.org\/10.1016\/j.annonc.2020.06.011.","journal-title":"Ann Oncol"},{"issue":"7","key":"3132_CR6","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1001\/jamaoncol.2024.1549","volume":"10","author":"O El-Taji","year":"2024","unstructured":"El-Taji O, Taktak S, Jones C, Brown M, Clarke N, Sachdeva A. Cardiovascular events and androgen receptor signaling inhibitors in advanced prostate cancer: a systematic review and meta-analysis. JAMA Oncol. 2024;10(7):874\u201384. https:\/\/doi.org\/10.1001\/jamaoncol.2024.1549.","journal-title":"JAMA Oncol"},{"key":"3132_CR7","unstructured":"Janssen Biotech. ZYTIGA 250\u00a0mg tablets Summary of Product Characteristics. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/zytiga-epar-product-information_en.pdf. Accessed 13 Aug 2024."},{"key":"3132_CR8","unstructured":"Astellas Pharma. Xtandi - 40\u00a0mg soft capsules Summary of Product Characteristics. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/xtandi-epar-product-information_en.pdf. Accessed 13 Aug 2024."},{"key":"3132_CR9","doi-asserted-by":"publisher","first-page":"555475","DOI":"10.3389\/fphar.2020.555475","volume":"11","author":"M Wilk","year":"2020","unstructured":"Wilk M, Wa\u015bko-Grabowska A, Szmit S. Cardiovascular complications of prostate cancer treatment. Front Pharmacol. 2020;11:555475. https:\/\/doi.org\/10.3389\/fphar.2020.555475.","journal-title":"Front Pharmacol"},{"key":"3132_CR10","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1007\/s11136-008-9356-z","volume":"17","author":"LV van de Poll-Franse","year":"2008","unstructured":"van de Poll-Franse LV, Sadetsky N, Kwan L, Litwin MS. Severity of cardiovascular disease and health-related quality of life in men with prostate cancer: a longitudinal analysis from CaPSURE. Qual Life Res. 2008;17:845\u201355. https:\/\/doi.org\/10.1007\/s11136-008-9356-z.","journal-title":"Qual Life Res"},{"key":"3132_CR11","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1016\/s1470-2045(12)70379-0","volume":"13","author":"K Fizazi","year":"2012","unstructured":"Fizazi K, Scher HI, Molina A, et al. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase\u00a03 study. Lancet Oncol. 2012;13:983\u201392. https:\/\/doi.org\/10.1016\/s1470-2045(12)70379-0.","journal-title":"Lancet Oncol"},{"key":"3132_CR12","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.eururo.2017.08.035","volume":"74","author":"K Miller","year":"2018","unstructured":"Miller K, Carles J, Gschwend JE, Van Poppel H, Diels J, Brookman-May SD. The phase\u00a03 COU-AA-302 study of abiraterone acetate plus prednisone in men with chemotherapy-na\u00efve metastatic castration-resistant prostate cancer: stratified analysis based on pain, prostate-specific antigen, and Gleason score. Eur Urol. 2018;74:17\u201323. https:\/\/doi.org\/10.1016\/j.eururo.2017.08.035.","journal-title":"Eur Urol"},{"key":"3132_CR13","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1001\/jamaoncol.2019.4636","volume":"6","author":"AJ Armstrong","year":"2020","unstructured":"Armstrong AJ, Al-Adhami M, Lin P, et al. Association between new unconfirmed bone lesions and outcomes in men with metastatic castration-resistant prostate cancer treated with enzalutamide: secondary analysis of the PREVAIL and AFFIRM randomized clinical trials. JAMA Oncol. 2020;6:217\u201325. https:\/\/doi.org\/10.1001\/jamaoncol.2019.4636.","journal-title":"JAMA Oncol"},{"key":"3132_CR14","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1002\/pros.24510","volume":"83","author":"MM Conover","year":"2023","unstructured":"Conover MM, Weaver J, Fan B, et al. Cardiovascular outcomes among patients with castration-resistant prostate cancer: a comparative safety study using US administrative claims data. Prostate. 2023;83:729\u201339. https:\/\/doi.org\/10.1002\/pros.24510.","journal-title":"Prostate"},{"key":"3132_CR15","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.clgc.2021.08.009","volume":"20","author":"J Hu","year":"2022","unstructured":"Hu J, Aprikian AG, Vanhuyse M, Dragomir A. Comparative cardiovascular safety of novel hormonal agents in metastatic castration-resistant prostate cancer using real-world data. Clin Genitourin Cancer. 2022;20:17\u201324. https:\/\/doi.org\/10.1016\/j.clgc.2021.08.009.","journal-title":"Clin Genitourin Cancer"},{"key":"3132_CR16","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.acvd.2019.09.006","volume":"113","author":"M Bretagne","year":"2020","unstructured":"Bretagne M, Lebrun-Vignes B, Pariente A, et al. Heart failure and atrial tachyarrhythmia on abiraterone: a pharmacovigilance study. Arch Cardiovasc Dis. 2020;113:9\u201321. https:\/\/doi.org\/10.1016\/j.acvd.2019.09.006.","journal-title":"Arch Cardiovasc Dis"},{"key":"3132_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2021.100887","volume":"36","author":"EB Cone","year":"2021","unstructured":"Cone EB, Reese S, Marchese M, et al. Cardiovascular toxicities associated with abiraterone compared to enzalutamide\u2014a pharmacovigilance study. EClinicalMedicine. 2021;36:100887. https:\/\/doi.org\/10.1016\/j.eclinm.2021.100887.","journal-title":"EClinicalMedicine"},{"key":"3132_CR18","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1038\/s41391-021-00318-3","volume":"24","author":"ST Tagawa","year":"2021","unstructured":"Tagawa ST, Ramaswamy K, Huang A, et al. Survival outcomes in patients with chemotherapy-naive metastatic castration-resistant prostate cancer treated with enzalutamide or abiraterone acetate. Prostate Cancer Prostatic Dis. 2021;24:1032\u201340. https:\/\/doi.org\/10.1038\/s41391-021-00318-3.","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"3132_CR19","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1038\/s41391-022-00588-5","volume":"26","author":"MW Schoen","year":"2023","unstructured":"Schoen MW, Carson KR, Eisen SA, et al. Survival of veterans treated with enzalutamide and abiraterone for metastatic castrate resistant prostate cancer based on comorbid diseases. Prostate Cancer Prostatic Dis. 2023;26:743\u201350. https:\/\/doi.org\/10.1038\/s41391-022-00588-5.","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"3132_CR20","doi-asserted-by":"publisher","DOI":"10.1038\/s41391-024-00816-0","author":"DJ George","year":"2024","unstructured":"George DJ, Ramaswamy K, Yang H, et al. Real-world overall survival with abiraterone acetate versus enzalutamide in chemotherapy-na\u00efve patients with metastatic castration-resistant prostate cancer. Prostate Cancer Prostatic Dis. 2024. https:\/\/doi.org\/10.1038\/s41391-024-00816-0.","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"3132_CR21","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1093\/aje\/kwaa190","volume":"190","author":"L-M Scailteux","year":"2021","unstructured":"Scailteux L-M, Campillo-Gimenez B, Kerbrat S, et al. Overall survival among chemotherapy-naive patients with castration-resistant prostate cancer under abiraterone versus enzalutamide: a direct comparison based on a 2014\u20132018 French population study (the SPEAR cohort). Am J Epidemiol. 2021;190:413\u201322. https:\/\/doi.org\/10.1093\/aje\/kwaa190.","journal-title":"Am J Epidemiol"},{"issue":"1","key":"3132_CR22","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.clgc.2021.08.009","volume":"20","author":"J Hu","year":"2022","unstructured":"Hu J, Aprikian AG, Vanhuyse M, Dragomir A. Comparative cardiovascular safety of novel hormonal agents in metastatic castration-resistant prostate cancer using real-world data. Clin Genitourin Cancer. 2022;20(1):17\u201324.","journal-title":"Clin Genitourin Cancer"},{"issue":"19","key":"3132_CR23","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.2217\/fon-2023-1065","volume":"20","author":"G Niegisch","year":"2024","unstructured":"Niegisch G, Grimm M-O, Hardtstock F, et al. Treatment patterns and clinical outcomes in metastatic urothelial carcinoma: a German retrospective real-world analysis. Future Oncol. 2024;20(19):1351\u201366. https:\/\/doi.org\/10.2217\/fon-2023-1065.","journal-title":"Future Oncol"},{"key":"3132_CR24","unstructured":"Verbraucherschutz BdJuf. Zehntes Buch Sozialgesetzbuch - Sozialverwaltungsverfahren und ozialdatenschutz - (SGB X) \u00a7 75 \u00dcbermittlung von Sozialdaten f\u00fcr die Forschung und Planung. 2022. https:\/\/dejure.org\/gesetze\/SGB_X\/75.html. Accessed 23 Jan 2024."},{"key":"3132_CR25","unstructured":"Deeks JJ, Higgins JPT, Altman DG, eds. Chapter 10: Analysing data and undertaking meta-analyses. In: Higgins JPT, Thomas J, Chandler J, et al, editors. Cochrane Handbook for Systematic Reviews of Interventions. Version 6.4 (updated August 2023). Cochrane, 2023. www.training.cochrane.org\/handbook. Accessed 13 Aug 2024."},{"key":"3132_CR26","doi-asserted-by":"publisher","first-page":"812","DOI":"10.21037\/atm-20-3998","volume":"9","author":"QY Zhao","year":"2021","unstructured":"Zhao QY, Luo JC, Su Y, Zhang YJ, Tu GW, Luo Z. Propensity score matching with R: conventional methods and new features. Ann Transl Med. 2021;9:812. https:\/\/doi.org\/10.21037\/atm-20-3998.","journal-title":"Ann Transl Med"},{"key":"3132_CR27","doi-asserted-by":"publisher","first-page":"e645","DOI":"10.1016\/j.clgc.2017.12.007","volume":"16","author":"R Iacovelli","year":"2018","unstructured":"Iacovelli R, Ciccarese C, Bria E, et al. The cardiovascular toxicity of abiraterone and enzalutamide in prostate cancer. Clin Genitourin Cancer. 2018;16:e645\u201353. https:\/\/doi.org\/10.1016\/j.clgc.2017.12.007.","journal-title":"Clin Genitourin Cancer"},{"key":"3132_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2021.100261","volume":"6","author":"A Kulkarni","year":"2021","unstructured":"Kulkarni A, Rubin N, Tholkes A, et al. Risk for stroke and myocardial infarction with abiraterone versus enzalutamide in metastatic prostate cancer patients. ESMO Open. 2021;6:100261. https:\/\/doi.org\/10.1016\/j.esmoop.2021.100261.","journal-title":"ESMO Open"},{"key":"3132_CR29","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.42533","volume":"15","author":"BI Nkwocha","year":"2023","unstructured":"Nkwocha BI, Singh M. Abiraterone-induced hypokalemia: a case report. Cureus. 2023;15:e42533. https:\/\/doi.org\/10.7759\/cureus.42533.","journal-title":"Cureus"},{"key":"3132_CR30","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.22940","volume":"14","author":"M Thu Kyaw","year":"2022","unstructured":"Thu Kyaw M, Maung ZM. Hypokalemia-induced arrhythmia: a case series and literature review. Cureus. 2022;14:e22940. https:\/\/doi.org\/10.7759\/cureus.22940.","journal-title":"Cureus"},{"key":"3132_CR31","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/s40264-019-00867-6","volume":"43","author":"NM Schultz","year":"2020","unstructured":"Schultz NM, Penson DF, Wilson S, et al. Adverse events associated with cumulative corticosteroid use in patients with castration-resistant prostate cancer: an administrative claims analysis. Drug Saf. 2020;43:23\u201333. https:\/\/doi.org\/10.1007\/s40264-019-00867-6.","journal-title":"Drug Saf"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03132-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-025-03132-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03132-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,23]],"date-time":"2025-03-23T07:07:19Z","timestamp":1742713639000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-025-03132-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,2]]},"references-count":31,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["3132"],"URL":"https:\/\/doi.org\/10.1007\/s12325-025-03132-8","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,2]]},"assertion":[{"value":"5 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Carsten-Henning Ohlmann: received support for the present publication from Astellas; received payment or honoraria for lectures, presentations, speakers bureaus, publication writing or educational events from Astellas, Janssen-Cilag, and AstraZeneca; received payment for expert testimony from Janssen-Cilag; received support for attending meetings and\/or travel from Bayer and Janssen-Cilag; and participated on a data safety monitoring board or advisory board of Bayer, Janssen-Cilag, and AstraZeneca. Axel S. Merseburger: received support for the present publication from Astellas; received payment or honoraria for lectures, presentations, speaker bureaus, publication writing, or educational events from Janssen, Astellas, and Bayer. He is an Editorial Board member of Advances in Therapy. He was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions. Armen Aprikian: received payment or honoraria for lectures, presentations, speaker bureaus, publication writing, or educational events; received support for attending meetings and\/or travel from Tolmar and Tersera; and has leadership or fiduciary role in other board, society, committee, or advocacy group, paid or unpaid for Canadian Urology Association and Cedars Cancer Foundation. Alexis Serikoff: received support for the present publication from Astellas. Andrew Chilelli: received support for the present publication and attending meetings and\/or travel from Astellas. Eugen Dornstauder: received support for the present publication from Astellas. Andrew Chilelli, Eugen Dornstauder, Matthias Stoelzel, Alexis Serikoff: full-time employees of Astellas Pharma. Sophia Junker: is an employee of Ingress-Health HWM GmbH, a Cytel Company that was contracted by Astellas Pharma Europe Ltd. to conduct this research. Philipp Hahn: is an employee of IPAM e.V. that was contracted by Cytel to conduct this research. Stefan G. Spitzer: has received support from Astellas as a consultant.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"Since this study was based on anonymized and nonidentifiable data, no informed consent or ethics approval from an institutional review board was required. The research followed legal and internal standard processes of database handlers that communicated only aggregated findings with the sponsor. Permission was obtained to access and use patient-level data from AOK PLUS and GWQ, in line with data protection concepts of relevant local regulations [].","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}